鼻咽癌组织中CD133的表达情况与放疗预后的关系研究
|
摘要
目的分析鼻咽癌癌组织中CD133的表达情况与放疗预后的关系。方法选取我院2013年7月至2015年6月期间收治的经病理活检确诊的初治鼻咽癌患者50例,采用免疫组织化学染色方法分析活检的鼻咽病变组织CD133蛋白表达情况,然后行常规放射治疗,原发灶剂量68~72 Gy,评估放疗近期疗效,并进行预后随访。结果 (1)CD133蛋白在鼻咽癌组织中呈高表达,表现为胞膜及胞质呈棕色阳性染色,且阳性表达率68. 00%。(2)CD133蛋白在鼻咽癌组织中的表达与TNM分期、淋巴结转移及放化疗疗效有关(P <0. 05),与年龄、性别等无关(P> 0. 05),其中CD133蛋白阳性表达者放疗后RR为61. 76%明显低于阴性表达者的93. 75%(P <0. 05)。(3)CD133蛋白阳性表达者放化疗后3年总生存率、无进展生存率分别为67. 65%、35. 29%明显低于阴性表达者的93. 75%、68. 75%(P <0. 05)。结论 CD133作为鼻咽癌干细胞较特异的表面标志物,在鼻咽癌组织呈高表达,与肿瘤病理特征密切相关,且可作为放疗预后的预测指标。
Objective To analyze the relationship between the expression of CD133 in nasopharyngeal carcinoma(NPC) tissues and the prognosis after radiotherapy. Methods 50 cases of patients with newNPC confirmed by pathology and biopsy in our hospital from July 2013 to June 2015 were selected as NPC group and treated with conventional radiotherapy. Immunohistochemical staining was used to analyze the expression of CD133 protein in the tissue of nasopharyngeal lesions. The primary dose was 68-72 Gy,the short-term efficacy of radiotherapy was evaluated,and all subjects were followed up. Results(1) The high expression of CD133 protein in the carcinoma tissue of nasopharyngeal carcinoma group showed that the positive expression rate was 68% in the cytoplasm and the cytoplasm of the cell membrane.(2) The expression of CD133 protein in NPC tissues was related to TNMstage,lymph node metastasis and chemotherapy(P < 0. 05),but not related to age or gender(P > 0. 05). RR of patients with positive expression of CD133 protein after radiotherapy was significantly lower than that of those with negative expression(61. 76% vs 93. 75%)(P <0. 05).(3) After radiotherapy,the 3-year overall survival rate and progression free survival rate of patients with positive expression of CD133 protein were significantly lower than those in those with negative expression(67. 65% and 35. 29% vs 93. 75% and 68. 75%)(P < 0. 05). Conclusion CD133 is a specific surface marker of NPC stem cells. It is highly expressed in NPC tissues and is closely related to tumor pathological features,which can be used as a predictive factor for the prognosis after radiotherapy.
Objective To analyze the relationship between the expression of CD133 in nasopharyngeal carcinoma(NPC) tissues and the prognosis after radiotherapy. Methods 50 cases of patients with newNPC confirmed by pathology and biopsy in our hospital from July 2013 to June 2015 were selected as NPC group and treated with conventional radiotherapy. Immunohistochemical staining was used to analyze the expression of CD133 protein in the tissue of nasopharyngeal lesions. The primary dose was 68-72 Gy,the short-term efficacy of radiotherapy was evaluated,and all subjects were followed up. Results(1) The high expression of CD133 protein in the carcinoma tissue of nasopharyngeal carcinoma group showed that the positive expression rate was 68% in the cytoplasm and the cytoplasm of the cell membrane.(2) The expression of CD133 protein in NPC tissues was related to TNMstage,lymph node metastasis and chemotherapy(P < 0. 05),but not related to age or gender(P > 0. 05). RR of patients with positive expression of CD133 protein after radiotherapy was significantly lower than that of those with negative expression(61. 76% vs 93. 75%)(P <0. 05).(3) After radiotherapy,the 3-year overall survival rate and progression free survival rate of patients with positive expression of CD133 protein were significantly lower than those in those with negative expression(67. 65% and 35. 29% vs 93. 75% and 68. 75%)(P < 0. 05). Conclusion CD133 is a specific surface marker of NPC stem cells. It is highly expressed in NPC tissues and is closely related to tumor pathological features,which can be used as a predictive factor for the prognosis after radiotherapy.
引文
[1]谷琳琳,张阳.前列腺癌过表达蛋白1作为鼻咽癌患者疾病预后不良生物标志物的可行性研究[J].标记免疫分析与临床,2016,23(8):926-931.
[2]陈荣梅,葛晓峰.鼻咽癌组织中HIF-1α、GLUT-1的表达与放疗敏感性关系的研究进展[J].实用肿瘤学杂志,2013,27(5):452-456.
[3]刘爱华,何安兵,童文先,等.凋亡抑制蛋白Livin表达与鼻咽癌放疗预后的相关性分析[J].临床肿瘤学杂志,2016,21(11):985-989.
[4]ARGAW-DENBOBA A,BALESTRIERI E,SERAFINO A,et al.HERV-K activation is strictly required to sustain CD133+melanoma cells with stemness features[J]. J Exp Clin Cancer Res,2017,36(1):20.
[5]YOU R,ZOU X,WANG S L,et al. New surgical staging system for patients with recurrent nasopharyngeal carcinoma based on the AJCC/UICC r TNM classification system[J]. Eur J Cancer,2015,51(13):1771-1779.
[6]EISENHAUER E A,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumors:RECIST guideline(version 1. 1)[J]. Eur J Cancer,2009,45(2):228-247.
[7]李威,姜波健,俞继卫. CD44与CD133蛋白在胃癌组织中的表达及其临床意义[J].中国普外基础与临床杂志,2014,21(1):21-28.
[8]龙金华,宝莹娜,金风,等.肿瘤干细胞标记物CD133在鼻咽癌组织中的表达及其临床意义[J].现代肿瘤医学,2012,20(8):1585-1588.
[9]SINGH SK,CLARKE D,TERASAKI M,et al. Identification of a cancer stem cell in human brain tumors[J]. Cancer Res,2003,63(18):5821-5828.
[10]陈斌,沈顺利,彭宝岗.微小RNA let-7a对CD133+肝癌干细胞增殖和转移的影响[J].中华细胞与干细胞杂志(电子版),2015,5(3):44-47.
[11]席小龙,姜波健,俞继卫. HOTAIR在CD133阳性胃癌细胞中的表达及其作用研究[J].中国普外基础与临床杂志,2015,22(6):659-664.
[12]高远,冯军,吴灵芝,等. CD133+肺癌干细胞中基质金属蛋白酶9和缺氧诱导因子2α的表达及其病理学机制[J].中华医学杂志,2015,95(32):2607-2611.
[13]NOMURA A,BANERJEE S,CHUGH R,et al. CD133 initiates tumors,induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer[J]. Oncotarget,2015,6(10):8313-8322.
[14]CIOFFI M,D'ALTERIO C,CAMERLINGO R,et al. Identification of a distinct population of CD133+CXCR4+cancer stem cells in ovarian cancer[J]. Sci Rep,2015,5:10357.
[15]张泽峰,高峰,王涛,等. CD133蛋白在非小细胞肺癌组织中的表达及其与临床病理参数及预后的关系[J].现代生物医学进展,2016,16(28):5575-5578.
[16]刘双,唐敏,甘生敏,等. X射线增强CD133-鼻咽癌细胞干样能力的研究[J].免疫学杂志,2016,32(6):491-495.
[17]江庆萍,谢思明,王爽,等.鼻咽癌干细胞标志物的检测意义[J].实用癌症杂志,2014,29(8):889-892.
[18]付汐,卢国英,李志辉,等.干细胞标记物CD133及CK19在鼻咽癌的表达及其临床意义[J].医学临床研究,2014,31(8):1485-1487.
[19]姜林鹤,宋云骏,刘运江,等. CD133在结直肠癌组织中的表达及其与患者预后关系的研究[J].临床和实验医学杂志,2015,14(9):723-725.
[20]王欢,乔俏,解海涛,等.鼻咽癌p-IRE1蛋白表达与放射治疗预后的关系[J].中国医科大学学报,2016,45(10):926-931.
[2]陈荣梅,葛晓峰.鼻咽癌组织中HIF-1α、GLUT-1的表达与放疗敏感性关系的研究进展[J].实用肿瘤学杂志,2013,27(5):452-456.
[3]刘爱华,何安兵,童文先,等.凋亡抑制蛋白Livin表达与鼻咽癌放疗预后的相关性分析[J].临床肿瘤学杂志,2016,21(11):985-989.
[4]ARGAW-DENBOBA A,BALESTRIERI E,SERAFINO A,et al.HERV-K activation is strictly required to sustain CD133+melanoma cells with stemness features[J]. J Exp Clin Cancer Res,2017,36(1):20.
[5]YOU R,ZOU X,WANG S L,et al. New surgical staging system for patients with recurrent nasopharyngeal carcinoma based on the AJCC/UICC r TNM classification system[J]. Eur J Cancer,2015,51(13):1771-1779.
[6]EISENHAUER E A,THERASSE P,BOGAERTS J,et al. New response evaluation criteria in solid tumors:RECIST guideline(version 1. 1)[J]. Eur J Cancer,2009,45(2):228-247.
[7]李威,姜波健,俞继卫. CD44与CD133蛋白在胃癌组织中的表达及其临床意义[J].中国普外基础与临床杂志,2014,21(1):21-28.
[8]龙金华,宝莹娜,金风,等.肿瘤干细胞标记物CD133在鼻咽癌组织中的表达及其临床意义[J].现代肿瘤医学,2012,20(8):1585-1588.
[9]SINGH SK,CLARKE D,TERASAKI M,et al. Identification of a cancer stem cell in human brain tumors[J]. Cancer Res,2003,63(18):5821-5828.
[10]陈斌,沈顺利,彭宝岗.微小RNA let-7a对CD133+肝癌干细胞增殖和转移的影响[J].中华细胞与干细胞杂志(电子版),2015,5(3):44-47.
[11]席小龙,姜波健,俞继卫. HOTAIR在CD133阳性胃癌细胞中的表达及其作用研究[J].中国普外基础与临床杂志,2015,22(6):659-664.
[12]高远,冯军,吴灵芝,等. CD133+肺癌干细胞中基质金属蛋白酶9和缺氧诱导因子2α的表达及其病理学机制[J].中华医学杂志,2015,95(32):2607-2611.
[13]NOMURA A,BANERJEE S,CHUGH R,et al. CD133 initiates tumors,induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer[J]. Oncotarget,2015,6(10):8313-8322.
[14]CIOFFI M,D'ALTERIO C,CAMERLINGO R,et al. Identification of a distinct population of CD133+CXCR4+cancer stem cells in ovarian cancer[J]. Sci Rep,2015,5:10357.
[15]张泽峰,高峰,王涛,等. CD133蛋白在非小细胞肺癌组织中的表达及其与临床病理参数及预后的关系[J].现代生物医学进展,2016,16(28):5575-5578.
[16]刘双,唐敏,甘生敏,等. X射线增强CD133-鼻咽癌细胞干样能力的研究[J].免疫学杂志,2016,32(6):491-495.
[17]江庆萍,谢思明,王爽,等.鼻咽癌干细胞标志物的检测意义[J].实用癌症杂志,2014,29(8):889-892.
[18]付汐,卢国英,李志辉,等.干细胞标记物CD133及CK19在鼻咽癌的表达及其临床意义[J].医学临床研究,2014,31(8):1485-1487.
[19]姜林鹤,宋云骏,刘运江,等. CD133在结直肠癌组织中的表达及其与患者预后关系的研究[J].临床和实验医学杂志,2015,14(9):723-725.
[20]王欢,乔俏,解海涛,等.鼻咽癌p-IRE1蛋白表达与放射治疗预后的关系[J].中国医科大学学报,2016,45(10):926-931.